



**Azarga Uranium Corp.**  
**CONSOLIDATED FINANCIAL STATEMENTS**

**December 31, 2017**  
(Expressed in U.S. Dollars)



Tel: 604 688 5421  
Fax: 604 688 5132  
www.bdo.ca

BDO Canada LLP  
600 Cathedral Place  
925 West Georgia Street  
Vancouver BC V6C 3L2 Canada

---

## Independent Auditor's Report

---

### To the Shareholders of Azarga Uranium Corp.

We have audited the accompanying consolidated financial statements of Azarga Uranium Corp., which comprise the consolidated statements of financial position as at December 31, 2017 and December 31, 2016, and the consolidated statements of loss and comprehensive loss, changes in equity and cash flows for the years then ended, and a summary of significant accounting policies and other explanatory information.

### Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

### Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained in our audits is sufficient and appropriate to provide a basis for our audit opinion.

### Opinion

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Azarga Uranium Corp. as at December 31, 2017 and December 31, 2016 and the consolidated statements of loss and comprehensive loss, changes in equity and cash flows for the years then ended, and a summary of significant accounting policies and other explanatory information in accordance with International Financial Reporting Standards.

### Emphasis of Matter

Without qualifying our opinion, we draw attention to Note 1 in the consolidated financial statements, which indicates that the Company has not generated revenues from operations, is currently in the exploration and development stage and has an accumulated deficit of \$16,593,976. These conditions, along with other matters as set forth in Note 1, indicate the existence of material uncertainties that may cast significant doubt upon the Company's ability to continue as a going concern.

(signed) "BDO CANADA LLP"

Chartered Professional Accountants  
Vancouver, Canada  
March 27, 2018

# TABLE OF CONTENTS

## CONSOLIDATED FINANCIAL STATEMENTS

	<i>Page</i>
Consolidated Statements of Financial Position	4
Consolidated Statements of Loss and Comprehensive Loss	5
Consolidated Statements of Changes in Equity	6
Consolidated Statements of Cash Flows	7

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1. Corporate information and going concern	8
2. Basis of preparation	8
3. Summary of significant accounting policies	10
4. Segmented information	25
5. Investments held for sale	26
6. Exploration and evaluation assets	27
7. Loans payable	29
8. Decommissioning liability	32
9. Warrant liabilities	33
10. Equity	33
11. Share option reserve	38
12. Administrative expenses	40
13. Finance costs	40
14. Unrealized gain (loss)	40
15. Realized gain (loss)	41
16. Related party transactions	41
17. Financial instruments and risk management	43
18. Capital risk management	47
19. Commitments	48
20. Supplemental cash flow information	48
21. Non-controlling interest	49
22. Deferred income tax	51
23. Subsequent events	53

**AZARGA URANIUM CORP.**  
**Consolidated Statements of Financial Position**  
*(Expressed in U.S. Dollars)*

		As at December 31,	
	Notes	2017	2016
<b>ASSETS</b>			
<b>Current assets</b>			
Cash		\$ 432,192	\$ 941,370
Other assets		123,160	30,681
Investments held for sale	5	-	68,264
<b>Total current assets</b>		<b>555,352</b>	<b>1,040,315</b>
<b>Non-current assets</b>			
Restricted cash		39,176	42,687
Exploration and evaluation assets	6	33,003,670	38,284,484
Property, plant and equipment		97,322	105,819
<b>Total non-current assets</b>		<b>33,140,168</b>	<b>38,432,990</b>
<b>Total assets</b>		<b>\$ 33,695,520</b>	<b>\$ 39,473,305</b>
<b>LIABILITIES AND EQUITY</b>			
<b>Current liabilities</b>			
Trade and other payables		\$ 1,525,906	\$ 1,066,872
Loans payable	7	328,678	1,898,135
<b>Total current liabilities</b>		<b>1,854,584</b>	<b>2,965,007</b>
<b>Non-current liabilities</b>			
Trade and other payables	16	-	310,000
Loans payable	7	1,776,000	40,065
Deferred income tax liabilities	22	4,052,790	6,288,790
Decommissioning liability	8	142,918	129,933
Warrant liabilities	9	258,116	596,602
<b>Total non-current liabilities</b>		<b>6,229,824</b>	<b>7,365,390</b>
<b>Total liabilities</b>		<b>8,084,408</b>	<b>10,330,397</b>
<b>Equity</b>			
Common shares	10	41,286,853	39,762,939
Contributed surplus	10	768,652	793,625
Share option reserve	11	1,427,563	1,196,865
Foreign currency translation reserve		(827,984)	(842,006)
Accumulated deficit		(16,593,976)	(13,015,295)
Equity attributable to the equity holders of the Company		26,061,108	27,896,128
Non-controlling interest	21	(449,996)	1,246,780
<b>Total equity</b>		<b>25,611,112</b>	<b>29,142,908</b>
<b>Total liabilities and equity</b>		<b>\$ 33,695,520</b>	<b>\$ 39,473,305</b>

**Approved by the Board:**

“Joseph L. Havlin”, Director \_\_\_\_\_

“Richard F. Clement, Jr.”, Director \_\_\_\_\_

The accompanying notes are an integral part of these consolidated financial statements.

# AZARGA URANIUM CORP.

## Consolidated Statements of Loss and Comprehensive Loss

(Expressed in U.S. Dollars)

	Notes	Year ended December 31,	
		2017	2016
Administrative expenses	12	\$ (1,659,228)	\$ (1,554,213)
Foreign exchange gain		114,110	82,223
Impairment of exploration and evaluation assets	6	(6,346,899)	-
<b>Loss from operations</b>		<b>(7,892,017)</b>	<b>(1,471,990)</b>
Finance costs	13	(216,478)	(191,080)
Unrealized gain (loss)	14	595,801	(1,204,160)
Realized gain (loss)	15	(3,938)	20,285
<b>Loss before income tax</b>		<b>(7,516,632)</b>	<b>(2,846,945)</b>
Deferred income tax recovery (expense)	22	2,236,000	(266,000)
<b>Net loss</b>		<b>(5,280,632)</b>	<b>(3,112,945)</b>
<b>Other comprehensive income (loss)</b>			
<b>Item that may be reclassified subsequently as profit or loss</b>			
Foreign currency translation adjustment		19,197	280,876
<b>Total comprehensive loss</b>		<b>\$ (5,261,435)</b>	<b>\$ (2,832,069)</b>
<b>Net income (loss) attributable to:</b>			
Equity holders of the Company		(3,578,681)	(3,118,216)
Non-controlling interest		(1,701,951)	5,271
<b>Net loss</b>		<b>\$ (5,280,632)</b>	<b>\$ (3,112,945)</b>
<b>Other comprehensive income attributable to:</b>			
Equity holders of the Company		14,022	207,995
Non-controlling interest		5,175	72,881
<b>Other comprehensive income</b>		<b>\$ 19,197</b>	<b>\$ 280,876</b>
<b>Basic and diluted loss per share</b>		<b>\$ (0.07)</b>	<b>\$ (0.05)</b>
<b>Weighted average number of common shares outstanding</b>		<b>77,506,606</b>	<b>65,360,184</b>

The accompanying notes are an integral part of these consolidated financial statements.

**AZARGA URANIUM CORP.**  
**Consolidated Statements of Changes in Equity**  
*(Expressed in U.S. Dollars and shares)*

	Attributable to equity holders of the Company								
	Number of shares	Common shares	Contributed surplus	Share option reserve	Foreign currency translation reserve	Accumulated deficit	Total equity	Non-controlling interest	Total equity
<b>Balances, December 31, 2016</b>	74,766,046	\$ 39,762,939	\$ 793,625	\$ 1,196,865	\$ (842,006)	\$ (13,015,295)	\$ 27,896,128	\$ 1,246,780	\$ 29,142,908
Issuance of shares for private placements	6,626,938	1,089,008	-	-	-	-	1,089,008	-	1,089,008
Issuance of shares to settle ESPP	1,100,918	234,652	(234,652)	-	-	-	-	-	-
Issuance of shares to settle DSA	288,448	61,060	(61,060)	-	-	-	-	-	-
Issuance of shares to settle employee remuneration	750,000	123,466	(123,466)	-	-	-	-	-	-
Issuance of shares for services	87,500	15,728	-	-	-	-	15,728	-	15,728
Share-based compensation	-	-	-	230,698	-	-	230,698	-	230,698
Compensation settled by equity	-	-	394,205	-	-	-	394,205	-	394,205
Net loss for the year	-	-	-	-	-	(3,578,681)	(3,578,681)	(1,701,951)	(5,280,632)
Other comprehensive income for the year	-	-	-	-	14,022	-	14,022	5,175	19,197
<b>Balances, December 31, 2017</b>	<b>83,619,850</b>	<b>\$ 41,286,853</b>	<b>\$ 768,652</b>	<b>\$ 1,427,563</b>	<b>\$ (827,984)</b>	<b>\$ (16,593,976)</b>	<b>\$ 26,061,108</b>	<b>\$ (449,996)</b>	<b>\$ 25,611,112</b>

	Attributable to equity holders of the Company								
	Number of shares	Common shares	Contributed surplus	Share option reserve	Foreign currency translation reserve	Accumulated deficit	Total equity	Non-controlling interest	Total equity
<b>Balances, December 31, 2015</b>	60,332,314	\$ 37,256,196	\$ 766,630	\$ 1,021,099	\$ (1,050,001)	\$ (9,897,079)	\$ 28,096,845	\$ 1,168,628	\$ 29,265,473
Issuance of shares for private placements	9,243,336	1,303,553	-	-	-	-	1,303,553	-	1,303,553
Issuance of shares to settle trade and other payables	1,130,664	280,401	-	-	-	-	280,401	-	280,401
Issuance of shares to settle ESPP	1,465,950	343,718	(343,718)	-	-	-	-	-	-
Issuance of shares to settle DSA	640,656	158,464	(158,464)	-	-	-	-	-	-
Issuance of shares to settle employee remuneration	812,500	169,933	(169,933)	-	-	-	-	-	-
Issuance of shares to settle interest	1,140,626	250,674	282,126	-	-	-	532,800	-	532,800
Share-based compensation	-	-	-	175,766	-	-	175,766	-	175,766
Compensation settled by equity	-	-	416,984	-	-	-	416,984	-	416,984
Net income (loss) for the year	-	-	-	-	-	(3,118,216)	(3,118,216)	5,271	(3,112,945)
Other comprehensive income for the year	-	-	-	-	207,995	-	207,995	72,881	280,876
<b>Balances, December 31, 2016</b>	<b>74,766,046</b>	<b>\$ 39,762,939</b>	<b>\$ 793,625</b>	<b>\$ 1,196,865</b>	<b>\$ (842,006)</b>	<b>\$ (13,015,295)</b>	<b>\$ 27,896,128</b>	<b>\$ 1,246,780</b>	<b>\$ 29,142,908</b>

The accompanying notes are an integral part of these consolidated financial statements.

**AZARGA URANIUM CORP.**  
**Consolidated Statements of Cash Flows**  
*(Expressed in U.S. Dollars)*

**Azarga Uranium Corp.**  
**Consolidated Statements of Cash Flows**

	Notes	Year ended December 31,	
		2017	2016
<b>OPERATING ACTIVITIES</b>			
Net loss		\$ (5,280,632)	\$ (3,112,945)
Adjustments for:			
Depreciation		2,123	6,015
Share-based compensation	11	198,706	147,909
Impairment of exploration and evaluation assets	6	6,346,899	-
Deferred income tax (recovery) expense	22	(2,236,000)	266,000
Equity compensation expense	10	409,933	-
Finance costs	13	216,478	191,080
Unrealized (gain) loss	14	(595,801)	1,204,160
Realized (gain) loss	15	3,938	(20,285)
Unrealized foreign exchange gain		(33,500)	(17,883)
Operating cash flows before changes in non-cash working capital items		(967,856)	(1,335,949)
Change in other assets		(92,479)	(147,002)
Change in trade and other payables		242,166	(456,392)
Change in other liabilities		-	(8,836)
<b>Net cash used in operating activities</b>		<b>(818,169)</b>	<b>(1,948,179)</b>
<b>INVESTING ACTIVITIES</b>			
Sale of investments	5	71,106	1,096,659
Sale of exploration and evaluation assets	6	-	604,092
Expenditures on exploration and evaluation assets	6	(1,163,207)	(650,311)
Option payments received for exploration and evaluation assets	6	150,000	-
Sale (purchase) of property, plant and equipment		(1,350)	11,130
<b>Net cash generated by (used in) investing activities</b>		<b>(943,451)</b>	<b>1,061,570</b>
<b>FINANCING ACTIVITIES</b>			
Proceeds from issuance of common shares	10	1,353,937	1,701,930
Share issue costs	10	(55,006)	(51,408)
Payment of other loans payable	7	(50,000)	(60,000)
<b>Net cash generated by financing activities</b>		<b>1,248,931</b>	<b>1,590,522</b>
Effect of foreign exchange rate changes on cash		3,511	(1,870)
<b>Increase (decrease) in cash</b>		<b>(509,178)</b>	<b>702,043</b>
Cash, beginning of year		941,370	239,327
<b>Cash, end of year</b>		<b>\$ 432,192</b>	<b>\$ 941,370</b>

The accompanying notes are an integral part of these consolidated financial statements.

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **1. CORPORATE INFORMATION AND GOING CONCERN**

---

Azarga Uranium Corp. (“Azarga Uranium”) was incorporated on February 10, 1984 in British Columbia, Canada. Azarga Uranium’s common shares are publicly traded on the Toronto Stock Exchange (“TSX”) (Symbol: AZZ) and the Frankfurt Stock Exchange (Symbol: P8AA). Azarga Uranium, together with its subsidiaries (collectively referred to as the “Company”), is an integrated uranium exploration and development company.

The Company controls uranium properties located in the United States of America (“USA”) and in the Kyrgyz Republic. The Company’s Dewey Burdock Project, located in South Dakota, is the Company’s initial development priority. The Company also owns the Centennial Project in Colorado, the Aladdin Deposit in Wyoming, two uranium exploration properties in Wyoming and 70% of the Kyzyl Ompul Project in the Kyrgyz Republic.

The address of the Company’s corporate office and registered and records office is Unit 1 – 15782 Marine Drive, White Rock, BC, V4B 1E6.

These consolidated financial statements have been prepared on a going concern basis, which contemplates that the Company will continue operations for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business as they fall due. To date, the Company has not generated revenues from operations and is currently in the exploration and development stage. As at December 31, 2017, the Company had a working capital deficit of \$1,299,232 and an accumulated deficit of \$16,593,976 and will continue incurring losses in the foreseeable future. Additional funding will be required by the Company to complete its strategic objectives and continue as a going concern. There is no certainty that additional financing, at terms that are acceptable to the Company, will be available. These material uncertainties cast significant doubt on the Company’s ability to continue as a going concern. The Company has successfully raised financing in the past and will continue to assess available alternatives; however, there is no assurance that the Company will be able to raise additional funds in the future.

### **2. BASIS OF PREPARATION**

---

#### **2.1 Statement of compliance**

These consolidated financial statements, including comparatives, have been prepared in accordance with and using accounting policies in compliance with International Financial Reporting Standards (“IFRS”) and interpretations issued by the International Accounting Standards Board (“IASB”) and interpretations of the IFRS Interpretations Committee (“IFRIC”).

These consolidated financial statements for the year ended December 31, 2017 were approved and authorized for issue by the Company’s Board of Directors on March 22, 2018.



# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **2. BASIS OF PREPARATION (Continued)**

---

#### **2.2 Basis of presentation**

These consolidated financial statements have been prepared on a historical cost basis except for certain financial assets and financial liabilities, which are measured at fair value. The Company's financial instruments are further disclosed in Note 17 of these consolidated financial statements.

#### **2.3 Adoption of new and revised standards and interpretations**

The Company has adopted all new and revised standards and interpretations issued by the IASB or IFRIC effective January 1, 2017. The adoption of these standards did not have a material impact on the Company's consolidated financial statements.

#### **2.4 Standards issued but not yet effective**

The standards and interpretations that are issued up to the date of issuance of the Company's consolidated financial statements, but were not effective for the year ended December 31, 2017, are disclosed below. The Company intends to adopt these standards, if applicable, when they become effective.

##### **IFRS 9 – Financial Instruments (Effective January 1, 2018)**

IFRS 9 will replace IAS 39 – Financial Instruments: Recognition and Measurement. IFRS 9 provides a revised model for recognition and measurement of financial instruments and a single, forward-looking 'expected loss' impairment model. IFRS 9 also includes a revised approach to hedge accounting.

Under IFRS 9, the Company will have the option to designate equity securities as financial assets at fair value through other comprehensive income, where they will be recorded initially at fair value with changes in fair value recognized in other comprehensive income, which will not be subsequently transferred into profit or loss. The Company does not expect IFRS 9 to have a significant impact on the Company's financial statements.

##### **IFRS 15 – Revenue from Contracts with Customers (Effective January 1, 2018)**

IFRS 15 establishes a single five-step model framework for determining the nature, amount, timing and uncertainty of revenue and cash flows arising from a contract with a customer. IFRS 15 supercedes: IAS 11 – Construction Contracts; IAS 18 – Revenue; IFRIC 13 – Customer Loyalty Programmes; IFRIC 15 – Agreements for the Construction of Real Estate; IFRIC 18 – Transfers of Assets from Customers; and SIC 31 – Revenue – Barter Transactions involving Advertising Services.

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

### 2. BASIS OF PREPARATION (Continued)

#### 2.4 Standards issued but not yet effective (Continued)

The introduction of IFRS 15 is not expected to have a significant impact on the Company's financial statements.

IFRS 16 – Leases (Effective January 1, 2019)

IFRS 16 applies a control model to the identification of leases, distinguishing between a lease and a service contract on the basis of whether the customer controls the asset being leased. For those assets determined to meet the definition of a lease, IFRS 16 introduces significant changes to the accounting for the lessee, introducing a single, on-balance sheet accounting model that is similar to finance lease accounting, with limited exceptions for short-term leases or leases of low value assets. Lessor accounting remains similar to the current accounting practice.

The introduction of IFRS 16 is not expected to have a significant impact on the Company's financial statements, as the leases currently held by the Company are either leases to explore for uranium resources, which are exempt from IFRS 16, or relate to office leases which are not material.

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### 3.1 Basis of consolidation

The consolidated financial statements include the financial statements of Azarga Uranium and its controlled subsidiaries.

Name of subsidiary	Place of incorporation	Ownership interest at December 31, 2017	Principal activity
Powertech USA, Inc.	United States of America	100%	Operating uranium exploration company
Azarga Resources Limited	BVI	100%	Holding company
UrAsia in Kyrgyzstan LLC	Kyrgyz Republic	70%	Operating uranium exploration company
Azarga Resources (Hong Kong) Limited	Hong Kong	100%	Holding company
Azarga Resources Canada Ltd.	Canada	100%	Holding company
Azarga Resources USA Company	United States of America	100%	Holding company

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)**

---

The Company controls an entity when the Company is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity.

The results of subsidiaries acquired or disposed of during the year are included in the consolidated statements of profit or loss and other comprehensive income or loss from the effective date of acquisition or up to the effective date of disposal, as appropriate. All intercompany transactions, balances, income and expenses are eliminated in full on consolidation.

#### **3.2 Associates**

Associates are all entities over which the Company has significant influence but not control, generally accompanying a shareholding of between 20% and 50% of the voting rights. Investments in associates are accounted for using the equity method of accounting. Under the equity method, the investment is initially recognized at cost, and the carrying amount is increased or decreased to recognize the investor's share of the profit or loss of the investee after the date of acquisition. The carrying amount is further decreased by the investor's share of the payment of dividends by the investee after the date of acquisition. When the Company's share of losses in an associate equals or exceeds its interest in the associate, including any other unsecured receivables, the Company does not recognize further losses, unless it has incurred legal or constructive obligations or made payments on behalf of the associate. The Company's investment in associates includes goodwill recognized on acquisition.

The Company determines at each reporting date whether there is any objective evidence that the investment in the associate is impaired. If this is the case, the Company calculates the amount of impairment as the difference between the recoverable amount of the associate and its carrying value and recognizes the amount in the statements of profit or loss and other comprehensive income or loss.

Profits and losses resulting from upstream and downstream transactions between the Company and its associate are recognized in the Company's consolidated financial statements only to the extent of unrelated investor's interests in the associates. Unrealized losses are eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of associates have been changed where necessary to ensure consistency with the policies adopted by the Company.

Dilution gains and losses arising in investments in associates are recognized in profit or loss.

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)**

---

A step acquisition of an associate acquired in stages is accounted under the 'fair value as deemed cost' method. The cost of an associate acquired in stages is measured as the sum of the fair value of the interest previously held plus the fair value of any additional consideration transferred as of the date when the investment became an associate. Any acquisition related costs are expensed in the periods in which the costs are incurred.

#### **3.3 Functional and presentation currency**

The functional currency of each entity is determined by the currency of the primary economic environment in which the entity operates. The functional currency of each entity is the United States Dollar, with the exception of UrAsia in Kyrgyzstan LLC, whose functional currency is the Kyrgyz Som.

These consolidated financial statements are presented in United States Dollars.

#### **Transactions and balances**

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign currency monetary items are translated at the period-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined.

Exchange differences arising on the translation of monetary items or on settlement of monetary items are recognized in profit or loss in the consolidated statements of profit or loss and other comprehensive income or loss in the period in which they arise.

Exchange differences arising on the translation of non-monetary items are recognized in other comprehensive income or loss in the consolidated statements of profit or loss and other comprehensive income or loss to the extent that gains and losses arising on those non-monetary items are also recognized in other comprehensive income or loss. Where the non-monetary gain or loss is recognized in profit or loss, the exchange component is also recognized in profit or loss.

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)**

---

#### **Parent and subsidiary companies**

The financial position and results of operations whose functional currency is different from the presentation currency are translated as follows:

- Assets and liabilities are translated at period-end exchange rates prevailing at that reporting date; and
- Income and expenses are translated at the average exchange rates for the period.

Exchange differences are transferred directly to other comprehensive income or loss and are included in a separate component of shareholders' equity titled foreign currency translation reserve. These differences are recognized in profit or loss in the period in which the subsidiary is disposed of.

#### **3.4 Restricted cash**

In the USA, restricted cash consists of deposits held for collateral pursuant to bonds provided to state authorities in connection with exploration and evaluation property activities. In the Kyrgyz Republic, restricted cash consists of deposits made pursuant to the requirements of the Company's exploration license agreements. The Company makes such cash deposits for restoration provisions related to rehabilitation obligations.

#### **3.5 Property, plant and equipment**

Property, plant and equipment ("PPE") includes the Company's machinery and equipment, office equipment, furniture and fixtures, vehicles and buildings. PPE is stated at cost less accumulated depreciation and accumulated impairment losses.

##### **Initial recognition**

The cost of an item of PPE consists of the purchase price or construction cost, including vendor prepayments, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use, borrowing costs during construction, if applicable, and the estimated costs associated with dismantling and removing the assets.

##### **Depreciation**

Depreciation is recorded based on the cost of an item of PPE, less its estimated residual value, using the straight-line method over the following estimated useful lives:

- Machinery and equipment      5 to 10 years
- Vehicles                              3 years

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)**

---

#### **3.5 Property, plant and equipment (Continued)**

- Office equipment 3 to 5 years
- Furniture and fixtures 4 to 5 years
- Building 10 to 40 years

When major components of an item of PPE have different useful lives, they are accounted for as separate items of PPE and depreciated as per each component's useful life.

The cost of replacing a component of PPE is recognized as part of the carrying value of the item if it is probable that the future economic benefit will flow to the Company and its cost can be measured. The carrying amount of the replaced component is derecognized.

An item of PPE is derecognized upon disposal, when held for sale or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in profit or loss.

The Company conducts an annual assessment of the residual balances, estimated useful lives and depreciation methods being used for PPE and any changes arising from the assessment are applied by the Company prospectively.

#### **3.6 Exploration and evaluation assets**

Pre-exploration costs are expensed in the period in which they occur.

Exploration and evaluation expenditures are recognized as assets in the period in which they are incurred once the legal right to explore a property has been acquired. This includes any acquisition costs associated with such property. These direct expenditures include such costs as drilling/engineering, salaries and consulting, rehabilitation costs and license fees, inclusive of land payments and claims maintenance. Costs not directly attributable to exploration and evaluation activities, including general and administrative overhead costs, are expensed in the period in which they occur. Payments received by the Company from partners are credited to the capitalized cost of the exploration and evaluation asset. If the payments received exceed the capitalized cost of the exploration and evaluation asset, the excess is recognized as a gain.

The Company assesses exploration and evaluation assets for impairment when facts and circumstances suggest that the carrying amount of the asset may exceed its recoverable amount. Any such impairment charges will be written off to profit or loss.

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)**

---

#### **3.6 Exploration and evaluation assets (continued)**

Once the technical feasibility and commercial viability of extracting the resource has been determined and management plans to develop the property, the property will be considered a mine under development and will be classified as “mines under construction.”

Exploration and evaluation expenditures are classified as intangible assets.

#### **3.7 Rehabilitation provisions**

The Company recognizes provisions for statutory, contractual, constructive or legal obligations, including those associated with the reclamation of environmental disturbances caused by exploration and evaluation activities. The nature of the rehabilitation activities includes restoration, reclamation and re-vegetation of the affected exploration sites. Initially, a provision for a decommissioning liability is recognized as its present value in the period in which it is incurred. Upon initial recognition of the liability, a corresponding amount is added to the carrying amount of the related asset and the cost is amortized as an expense over the economic life of the asset using either the unit-of-production method or the straight-line method, as appropriate. Following the initial recognition of the decommissioning liability, the carrying amount of the liability is increased for the passage of time and adjusted for changes to the current market based discount rate and the amount or timing of the underlying cash flows needed to settle the obligation.

#### **3.8 Taxation**

Income tax expense represents the sum of current and deferred income tax.

##### **Current income tax**

Current income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to taxation authorities. The tax rates and tax laws used to compute current income taxes for each jurisdiction in which the Company operates, are those that are substantively enacted at the end of each reporting period. The Company incurred no current income taxes for the years ended December 31, 2017 and 2016.

##### **Deferred income tax**

Deferred income tax is provided for using the liability method on temporary differences, at the end of each reporting period, between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

Deferred income tax liabilities are recognized for all taxable temporary differences, except:

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)**

---

#### **3.8 Taxation (Continued)**

##### **Deferred income tax (Continued)**

- Where the deferred income tax liability arises from the initial recognition of goodwill or of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- In respect of taxable temporary differences associated with investments in subsidiaries, associates and joint ventures, where the timing of the reversal of the temporary differences can be controlled by the parent, investor or venturer and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred income tax assets are recognized for all deductible temporary differences, carry forward of unused tax credits and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilized except:

- Where the deferred income tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- In respect of deductible temporary differences associated with investments in subsidiaries, associates and joint ventures, deferred income tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.

The carrying amount of deferred income tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized.

Unrecognized deferred income tax assets are reassessed at the end of each reporting period and are recognized to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered. Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates and tax laws that have been substantively enacted at the end of each reporting period.

In consolidated financial statements, temporary differences are determined by comparing the carrying amounts of assets and liabilities in the consolidated financial statements with the appropriate tax base. The tax base is determined by reference to the tax returns of each entity in the group.



# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)**

---

#### **3.8 Taxation (Continued)**

##### **Deferred income tax (Continued)**

Deferred income tax relating to items recognized directly in equity or other comprehensive income or loss are recognized in equity and not in profit or loss or other comprehensive income or loss.

Deferred income tax assets and deferred income tax liabilities are offset if, and only if, a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred tax assets and liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities which intend to either settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax assets or liabilities are expected to be settled or recovered.

#### **3.9 Financial instruments**

##### **Financial assets**

All financial assets are initially recorded at fair value and designated upon inception into one of the following four categories: held-to-maturity, available-for-sale, loans-and-receivables or fair value through profit or loss.

Financial assets classified as fair value through profit or loss ("FVTPL") are measured at fair value with unrealized gains and losses recognized through profit or loss.

Financial assets classified as loans-and-receivables and held-to-maturity are measured at amortized cost using the effective interest method less any allowance for impairment. The effective interest rate is the rate that exactly discounts estimated future cash receipts, including all fees paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts, through the expected life of the financial asset, or, where appropriate, a shorter period.

Financial assets classified as available-for-sale are measured at fair value with unrealized gains and losses recognized in other comprehensive income or loss except when there is objective evidence that the financial asset is impaired. Impairment losses on available-for-sale financial assets are recognized in profit or loss.

Transaction costs associated with FVTPL financial assets are expensed as incurred, while transaction costs associated with all other financial assets are included in the initial carrying amount of the asset.

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)**

---

#### **3.9 Financial instruments (Continued)**

##### **Financial assets (Continued)**

Derivative instruments, including embedded derivatives, are carried at fair value with any changes in the fair values of derivative instruments being recognized in profit or loss with the exception of derivatives designated as effective cash flow hedges. The Company has no such designated hedges.

##### **Financial liabilities**

All financial liabilities are initially recorded at fair value and designated upon inception as FVTPL or other financial liabilities.

Financial liabilities classified as other financial liabilities are initially recognized at fair value less directly attributable transaction costs. After initial recognition, other financial liabilities are subsequently measured at amortized cost using the effective interest method. The effective interest rate is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability, or, where appropriate, a shorter period.

Financial liabilities classified as FVTPL include financial liabilities designated upon initial recognition as FVTPL. Transaction costs on financial liabilities classified as FVTPL are expensed as incurred. At the end of each reporting period, financial liabilities classified as FVTPL are measured at fair value, with changes in fair value recognized directly in profit or loss in the period in which they arise. The net gain or loss recognized in profit or loss excludes any interest paid on the financial liabilities.

Derivative instruments, including embedded derivatives, are carried at fair value with any changes in the fair values of derivative instruments being recognized in profit or loss with the exception of derivatives designated as effective cash flow hedges. The Company has no such designated hedges.

#### **3.10 Derivative financial instruments**

The Company may issue or hold compound financial instruments with embedded derivatives. An embedded derivative is separated from its host contract and accounted for as a derivative only when three criteria are satisfied:

- When the economic risks and characteristics of the embedded derivative are not closely related to those of the host contract;
- A separate instrument with the same terms as the embedded derivative would meet the definition of a derivative; and

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)**

---

#### **3.9 Financial instruments (Continued)**

##### **Derivative financial instruments (continued)**

- The entire instrument is not measured at fair value with changes in fair value recognized in the consolidated statements of profit or loss and other comprehensive income or loss.

##### **Financial assets**

The Company designates financial assets with embedded derivatives as FVTPL on the initial recognition and accordingly does not bifurcate between the host contract and the embedded derivative. The embedded derivative is measured at each reporting period using an appropriate valuation model with changes in the fair value being recognized immediately in profit or loss.

##### **Financial liabilities**

The Company designates certain financial liabilities with embedded derivatives as FVTPL on the initial recognition and accordingly does not bifurcate between the host contract and the embedded derivative. However, other financial liabilities with embedded derivatives are bifurcated depending on the instrument. In the case of the latter, the debt host component is classified as other financial liabilities and is measured at amortized cost using the effective interest rate method. The embedded derivatives are classified as FVTPL and all changes in fair value are recorded in profit or loss. The difference between the debt host component and the principal amount of the loan outstanding is recorded as profit or loss over the expected life of the financial liabilities.

#### **3.11 Impairment of financial assets**

##### **Assets carried at amortized cost**

The Company assesses at the end of each reporting period whether a financial asset is impaired.

If there is objective evidence that an impairment loss on assets carried at amortized cost has been incurred, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows discounted at the financial asset's original effective interest rate. The carrying amount of the asset is then reduced by the amount of the impairment. The amount of the loss is recognized in profit or loss.

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)**

---

#### **3.11 Impairment of financial assets (continued)**

##### **Assets carried at amortized cost (continued)**

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, the previously recognized impairment loss is reversed to the extent that the carrying value of the asset does not exceed what the amortized cost would have been had the impairment not been recognized. Any subsequent reversal of an impairment loss is recognized in profit or loss.

#### **3.12 Impairment of non-financial assets**

At the end of each reporting period, the Company reviews the carrying amounts of its tangible and intangible assets to determine whether there is an indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss, if any. Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit to which the assets belong.

The recoverable amount is the higher of fair value less costs to sell and value in use. In assessing fair value less costs to sell, recent market transactions are taken into account. The Company also considers the results of an appropriate valuation model, which would generally be determined based on the present value of estimated future cash flows arising from the continued use and eventual disposal of the asset. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects the current market and the risks specific to the asset.

If the recoverable amount of an asset or cash-generating unit is estimated to be less than its carrying amount, the carrying amount is reduced to its recoverable amount. The impairment loss is recognized in profit or loss.

Where an impairment loss subsequently reverses, the carrying amount is increased to the revised estimate of its recoverable amount, but not above the original carrying amount.

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)**

---

#### **3.13 Derecognition of financial assets and financial liabilities**

Financial assets are derecognized when the rights to receive cash flows from the assets expire or the Company has transferred substantially all the risks and rewards of ownership. On derecognition, the difference between the asset's carrying amount and the sum of the consideration received and receivable and the cumulative gain or loss that had been recognized directly in equity is recognized in profit or loss.

Financial liabilities are derecognized when the obligation specified in the underlying contract is discharged, cancelled or expired. The difference between the carrying amount of the financial liability derecognized and the consideration paid and payable is recognized in profit or loss, unless the financial liability is settled with the Company's shares, in which case it is recognized in profit or loss or equity.

#### **3.14 Share-based payment transactions**

##### **Equity-settled transactions**

For equity-settled plans, the grant date fair value of share-based compensation awards granted to employees, inclusive of directors of the Company (the "Employees"), is recognized as an expense or is capitalized as appropriate, with a corresponding increase in equity, over the period that the Employees unconditionally become entitled to the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and vesting conditions, if any, are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that meet the related service and non-market performance conditions at the vesting date.

Certain Employees of the Company receive a portion of their remuneration in the form of share-based payments.

##### **Cash-settled transactions**

For cash-settled plans, the fair value of the amount payable to Employees is recognized as an expense, with a corresponding increase in liabilities, over the period that the Employees unconditionally become entitled to payment. The liability is re-measured at each reporting date and at settlement date. Any changes in the fair value of the liability are recognized as an expense.

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)**

---

#### **3.14 Share-based payment transactions (continued)**

##### **Choice of settlement**

If the Company has a choice of whether to settle a share-based payment in cash or by issuing equity, the Company will record this as an equity-settled transaction, unless there is a present obligation to settle in cash, whereby the Company will record this as cash-settled transaction.

#### **3.15 Common shares**

Common shares are classified as equity. Costs directly attributable to the issuance of common shares are shown in equity as a reduction, net of tax, of the proceeds.

#### **3.16 Share purchase warrants**

Share purchase warrants are considered a derivative liability, as the currency denomination of the exercise price is different from the functional currency of the Company. As a result, the fair value of the share purchase warrants are calculated on the issuance date using the Black-Scholes Option Pricing model. Any foreign exchange or change in the fair value of the warrant subsequent to the initial recognition is recorded in profit or loss.

#### **3.17 Loss per share**

Basic loss per share is calculated by dividing the net loss attributable to equity holders of the Company by the weighted average number of shares outstanding during the reporting period.

Diluted loss per share is calculated by adjusting the net loss attributable to equity holders of the Company and the weighted average number of shares outstanding for the effects of all dilutive share equivalents. The Company's dilutive share equivalents include stock options, share purchase warrants and convertible securities.

In the Company's case, diluted loss per share is the same as basic loss per share, as the effect of outstanding share options on loss per share would be anti-dilutive.

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)**

---

#### **3.18 Related party transactions**

Parties are considered related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered related if they are subject to common control. Related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

#### **3.19 Segment reporting**

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the executive management that makes strategic decisions.

#### **3.20 Significant accounting judgments and estimates**

Information about judgments and estimates in applying accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements are as follows:

##### **Liquidity and going concern assumption**

In the determination of the Company's ability to meet its ongoing obligations and future contractual commitments management relies on the Company's planning, budgeting and forecasting process to help determine the funds required to support the Company's normal operations on an ongoing basis and its expansionary plans. The key inputs used by the Company in this process include forecasted capital deployment, progress on permitting, results from the exploration and development of its properties and general industry conditions. Changes in these inputs may alter the Company's ability to meet its ongoing obligations and future contractual commitments and could result in adjustments to the amounts and classifications of assets and liabilities should the Company be unable to continue as a going concern (Note 1).

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)**

---

#### **3.20 Significant accounting judgments and estimates (continued)**

##### **Review of carrying value of assets and impairment charges**

In the determination of carrying values and impairment charges, management of the Company reviews the higher of the recoverable amount and the fair value less costs to sell or the value in use in the case of non-financial assets and at objective evidence indicating impairment in the case of financial assets. These determinations and their individual assumptions require that management make a decision based on the best available information at each reporting period. Changes in these assumptions may alter the results of non-financial asset and financial asset impairment testing, impairment charges recognized in profit or loss and the resulting carrying amounts of assets.

As at each reporting date, the Company reviews assets to determine whether there is any indication that those assets have suffered an impairment loss.

During the year ended December 31, 2017, the Company recorded an impairment loss of \$6,346,899 on its Kyzul Ompul project in Kyrgyzstan (Note 6).

##### **Capitalization of exploration and evaluation costs**

Management has determined that exploration and evaluation costs incurred during the year will have future economic benefits and are economically recoverable. In making this judgment, management has assessed various sources of information including, but not limited to, the geologic and metallurgic information, history of conversion of mineral deposits to proven and probable mineral reserves, scoping studies, preliminary economic assessments, proximity of operating facilities, operating management expertise and existing permits.

#### **3.21 Comparative figures**

Certain comparative figures have been reclassified to conform to the financial statement presentation adopted for the current year.



# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

### 4. SEGMENTED INFORMATION

The Company has two reportable business segments: the United States Uranium Division and the Kyrgyzstan Uranium Division. The Company's chief operating decision maker reviews both business segments' discrete financial information in order to make decisions about resources to be allocated to each segment and to assess its performance.

The carrying amount of the Company's assets, liabilities and exploration and evaluation assets and the Company's loss before income tax and impairment of exploration and evaluation assets analyzed by operating segment are as follows:

	Kyrgyzstan Uranium Division	United States Uranium Division	Unallocated (i)	Consolidated Total
<b>Segment assets</b>				
As at December 31, 2017	\$ 4,141,856	\$ 29,288,567	\$ 265,097	\$ 33,695,520
As at December 31, 2016	\$ 10,402,932	\$ 28,120,831	\$ 949,542	\$ 39,473,305
<b>Segment liabilities</b>				
As at December 31, 2017	\$ 1,036,156	\$ 3,677,443	\$ 3,370,809	\$ 8,084,408
As at December 31, 2016	\$ 2,093,651	\$ 4,946,039	\$ 3,290,707	\$ 10,330,397
<b>Exploration and evaluation assets (Note 6)</b>				
As at December 31, 2017	\$ 4,069,145	\$ 28,934,525	\$ -	\$ 33,003,670
As at December 31, 2016	\$ 10,363,942	\$ 27,920,542	\$ -	\$ 38,284,484
<b>Loss before income tax</b>				
Year ended December 31, 2017	\$ (6,416,438)	\$ (271,561)	\$ (828,633)	\$ (7,516,632)
Year ended December 31, 2016	\$ (174,777)	\$ (193,604)	\$ (2,478,564)	\$ (2,846,945)
<b>Impairment of exploration and evaluation assets (Note 6)</b>				
Year ended December 31, 2017	\$ (6,346,899)	\$ -	\$ -	\$ (6,346,899)
Year ended December 31, 2016	\$ -	\$ -	\$ -	\$ -

(i) The unallocated amount contains all amounts associated with the corporate division.

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

### 5. INVESTMENTS HELD FOR SALE

#### 5.1 Investment in Uranium Resources, Inc.

	Year ended December 31,	
	2017	2016
Balance, beginning of year	\$ 68,264	\$ 1,132,695
Disposition of shares	(93,676)	(419,201)
Unrealized gain (loss) on revaluation of investment	25,412	(645,230)
Balance, end of year	\$ -	\$ 68,264

As at December 31, 2017, the Company no longer held an ownership interest in Uranium Resources, Inc. ("URI"). The Company accounted for its investment in URI as FVTPL and fair value changes were recorded through profit or loss.

During the year ended December 31, 2017, the Company sold its remaining 49,828 URI shares for proceeds of \$71,106 and recognized a realized loss of \$22,570. In addition, the Company also recorded an unrealized gain on revaluation of its investment in URI of \$25,412. During the year ended December 31, 2016, the Company sold 131,694 URI shares for proceeds of \$347,151 and recognized a realized loss of \$72,050. In addition, the Company also recorded an unrealized loss on revaluation of its investment in URI of \$645,230.

#### 5.2 Investment in Western Uranium Corporation

	Year ended December 31,	
	2017	2016
Balance, beginning of year	\$ -	\$ 1,195,960
Disposition of shares	-	(897,649)
Unrealized loss on revaluation of investment	-	(298,311)
Balance, end of year	\$ -	\$ -

As at December 31, 2016, the Company no longer held an ownership interest in Western Uranium Corporation ("Western Uranium"). The Company accounted for its investment in Western Uranium as FVTPL and fair value changes were recorded through profit or loss.

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

### 5. INVESTMENTS HELD FOR SALE (continued)

#### 5.2 Investment in Western Uranium Corporation

During the year ended December 31, 2016, the Company sold 645,399 Western Uranium shares for proceeds of \$749,508 and recognized a realized loss of \$148,141. In addition, the Company also recorded an unrealized loss on revaluation of its investment in Western Uranium of \$298,311.

### 6. EXPLORATION AND EVALUATION ASSETS

The Company's exploration and evaluation assets consist of the following amounts:

	South Dakota	Kyrgyzstan	Colorado	Wyoming	
	Dewey Burdock	Kyzyl Ompul	Centennial	Other	Total
Balance, December 31, 2016	\$ 25,073,304	\$ 10,363,942	\$ 2,288,492	\$ 558,746	\$ 38,284,484
Salaries and consulting	558,701	56,153	21,172	21,000	657,026
License fees	263,038	50,735	6,724	110,187	430,684
Decommissioning liability	-	-	12,985	-	12,985
Share-based compensation	14,492	11,816	2,842	2,842	31,992
Rehabilitation costs	-	2,269	-	-	2,269
Depreciation	-	7,901	-	-	7,901
Option payments received	-	(150,000)	-	-	(150,000)
Impairment	-	(6,346,899)	-	-	(6,346,899)
Currency translation effect	-	73,228	-	-	73,228
Balance, December 31, 2017	\$ 25,909,535	\$ 4,069,145	\$ 2,332,215	\$ 692,775	\$ 33,003,670

	South Dakota	Kyrgyzstan	Colorado	Wyoming	
	Dewey Burdock	Kyzyl Ompul	Centennial	Other	Total
Balance, December 31, 2015	\$ 24,649,275	\$ 9,908,668	\$ 2,189,362	\$ 426,870	\$ 37,174,175
Salaries and consulting	188,625	109,670	55,246	-	353,541
License fees	213,576	43,146	32,049	131,876	420,647
Decommissioning liability	-	-	11,835	-	11,835
Share-based compensation	21,828	6,029	-	-	27,857
Depreciation	-	5,997	-	-	5,997
Currency translation effect	-	290,432	-	-	290,432
Balance, December 31, 2016	\$ 25,073,304	\$ 10,363,942	\$ 2,288,492	\$ 558,746	\$ 38,284,484

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **6. EXPLORATION AND EVALUATION ASSETS (continued)**

---

#### **6.1 Dewey Burdock Project, South Dakota**

The Dewey Burdock Uranium Project is an in-situ recovery uranium project located in the Edgemont uranium district in South Dakota. The Dewey Burdock Uranium Project is the Company's initial development priority.

#### **6.2 Dewey Terrace Project, South Dakota**

The Dewey Terrace Uranium Project is located in the Weston and Niobrara Counties of Wyoming, adjacent to the Dewey Burdock Project.

#### **6.3 Kyzyl Ompul Project, Kyrgyz Republic**

The Kyzyl Ompul Project is 100% owned and operated by UrAsia in Kyrgyzstan LLC ("UrAsia"), in which the Company owns a 70% interest and consists of one exploration license. The license is valid until December 31, 2020 and permits exploration for uranium.

On July 31, 2017, UrAsia executed an earn-in agreement (the "Earn-In Agreement") with Mining Investment Company Alliance ("Alliance"). The Earn-In Agreement provides Alliance with an earn-in option to acquire a 100% interest in the Kyzyl Ompul Project in exchange for \$6.0 million of cash payments and a two percent net smelter royalty of up to \$5.0 million as well as Alliance making \$1.6 million of exploration and development expenditures over a three-year period. During the year ended December 31, 2017, UrAsia received \$150,000 in cash payments from Alliance. The remaining cash payments are expected to be received as follows: \$60,000 per month commencing February 1, 2018, increasing to \$229,000 per month commencing August 1, 2018, and a final payment of \$223,000 on July 1, 2020. Cash payments received from Alliance over the course of the Earn-In Agreement are not reimbursable if Alliance does not exercise its earn-in option.

The February 1 and March 1, 2018 cash payments have not yet been received and the Company is in discussions with Alliance to resolve this default using the remedies available to it under the Earn-In Agreement.

The net smelter royalty is subject to Alliance exercising its earn-in option and is payable on the commencement of commercial production at the Kyzyl Ompul Project for a minimum royalty of \$2.5 million and a maximum royalty of \$5.0 million. If Alliance fails to make any of the payments under the Earn-In Agreement, UrAsia has the right to retain its 100% interest in the Kyzyl Ompul Project.

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

### 6. EXPLORATION AND EVALUATION ASSETS (Continued)

#### 6.3 Kyzyl Ompul Project, Kyrgyz Republic (continued)

During the year ended December 31, 2017, the Company recognized an impairment charge of \$6,346,899 for the Kyzyl Ompul Project on execution of the Earn-In Agreement. The recoverable amount of the Kyzyl Ompul Project was based on a fair value less cost to sell model, which incorporated the net present value of expected cash flows in accordance with the Earn-In Agreement discounted at a rate of 22%. It was categorized as a non-recurring level 3 fair value measurement. The discount rate was determined based on a market participant's cost of capital, adjusted for political and development risks.

#### 6.4 Centennial Project, Colorado

The Centennial Uranium Project is located in the western part of Weld County in northeastern Colorado.

During the year ended December 31, 2016, the Company sold redundant land for net proceeds of \$604,092 resulting in a gain on sale of \$154,092.

### 7. LOANS PAYABLE

	As at December 31,	
	2017	2016
Loan payable to shareholders	\$ 2,057,805	\$ 1,848,135
Other loans payable	46,873	90,065
Loans payable	\$ 2,104,678	\$ 1,938,200
Current portion	\$ 328,678	\$ 1,898,135
Non-current portion	\$ 1,776,000	\$ 40,065

	As at December 31,	
	2017	2016
Loan payable to shareholders - current	\$ 281,805	\$ 1,848,135
Loan payable to shareholders - non-current	1,776,000	-
Loan payable to shareholders	\$ 2,057,805	\$ 1,848,135

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **7. LOANS PAYABLE (Continued)**

---

#### **7.1 Loan payable to shareholders**

On July 31, 2012, the Company entered into a \$1,800,000 convertible loan agreement with certain shareholders ("Shareholders Loan Agreement"), as amended. The proceeds were used to fund the UrAsia 2012 exploration program and for general working capital purposes. On June 30, 2017, the Company exercised its option to extend the term of the Shareholders Loan Agreement for an additional three years. The changes to the term of the Shareholders Loan Agreement was accounted for as a debt modification in accordance with IAS 39. The key commercial terms of the loan include:

- Interest – 15% per annum payable on each anniversary date of the Shareholders Loan Agreement (10% per annum prior to the Company's exercise of the term extension);
- Term – 8 years, commencing July 31, 2012;
- Conversion price – Canadian dollar ("C\$")1.23;
- Shareholders' conversion right – to convert the outstanding balance of the loan plus accrued interest, in whole or in part, into ordinary shares of the Company at the conversion price;
- Early repayment option – the Company has the right, but not the obligation, to repay the whole balance of the loan plus accrued interest at any time out of the proceeds of a capital raising or if the loan is refinanced or replaced by a new loan on or before the maturity; and
- The Shareholders Loan Agreement is unsecured.

The terms of the Shareholders Loan Agreement were also amended to defer the July 31, 2014 and 2015 annual interest payments until July 31, 2016. In May 2016, the Company entered into shares for debt settlement agreements for up to \$532,800 to settle the July 31, 2014, 2015 and 2016 annual interest payments. As a result, the Company issued 1,140,626 common shares to settle the outstanding interest of \$532,800 as at July 31, 2016.

In July 2017, the terms of the Shareholders Loan Agreement were further amended to defer the July 31, 2017 annual interest payment until July 31, 2018.

As at December 31, 2017, the Company had drawn \$1,776,000 under the Shareholders Loan Agreement and no additional amounts are available to be drawn. During the year ended December 31, 2017, the Company recorded interest expense on the convertible loan of \$209,670 (2016 - \$178,489).

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

### 7. LOANS PAYABLE (Continued)

#### 7.2 Other loans payable

	Year ended December 31,	
	2017	2016
Other loans payable - current	\$ 46,873	\$ 50,000
Other loans payable - non-current	-	40,065
Other loans payable	\$ 46,873	\$ 90,065

For the year ended December 31, 2017, the imputed effective interest expense on other loans payable was \$6,808 (2016 - \$10,012) and the Company made payments totaling \$50,000 (2016 - \$60,000).

#### Centennial Purchase Agreement

In 2006, the Company entered into an agreement, as amended, to purchase uranium rights on certain areas of the Centennial Project for consideration of \$1,895,000, excluding contingent payments. As at December 31, 2017, \$1,875,000 (2016 - \$1,855,000) had been paid. The outstanding consideration of \$20,000 is payable in September 2018. An additional \$3,165,000 is payable upon receipt of regulatory permits and licenses allowing uranium production on the area of the Centennial Project pertaining to these uranium interests. The Company has disclosed this amount as a commitment in Note 19. The Company has also agreed to purchase up to 1,280 surface acres at the Centennial Project upon receipt of regulatory permits and licenses allowing uranium production. The purchase price for the surface acres will be calculated using the then prevailing market rates; however, this amount cannot currently be reasonably quantified due to the uncertainty associated with the timing of receipt of the regulatory permits and licenses, the number of surface acres that will be purchased and the future prevailing market rates for the surface acres. If the Company does not obtain the regulatory permits and licenses allowing uranium production pertaining to the Centennial purchase agreement by September 27, 2019, the uranium rights will transfer back to the seller, at seller's option.

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### 7. LOANS PAYABLE (Continued)

---

#### 7.2 Other loans payable (Continued)

##### Dewey Burdock Purchase Agreements

In 2006 and 2008, the Company entered into agreements to purchase mineral rights on certain areas of the Dewey Burdock Project for consideration of \$800,000, excluding contingent payments. As at December 31, 2017, \$770,000 (2016 - \$740,000) had been paid. The outstanding consideration of \$30,000 is payable in May 2018. An additional \$2,050,000 is payable, in four equal annual installments, commencing 12 months subsequent to the receipt of regulatory permits and licenses allowing uranium production on the area of the Dewey Burdock Project pertaining to these mineral interests. The Company has disclosed this amount as a commitment in Note 19.

The Centennial and Dewey Burdock purchase agreements are classified as other financial liabilities and are measured at amortized cost using the effective interest rate method.

### 8. DECOMMISSIONING LIABILITY

---

	Year ended December 31,	
	2017	2016
Balance, beginning of year	\$ 129,933	\$ 118,097
Accretion	12,985	11,836
Balance, end of year	\$ 142,918	\$ 129,933

The decommissioning liability includes the estimated reclamation costs on exploration wells at the Centennial project. The Company has recorded the present value of the liability based on the assumption that \$168,806 will be paid out in September 2019.



# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

### 9. WARRANT LIABILITIES

	Year ended December 31,	
	2017	2016
Balance, beginning of year	\$ 596,602	\$ 3,809
Issuance of warrants	209,923	346,969
(Gain) loss on revaluation	(570,389)	260,619
Currency translation effect	21,980	(14,795)
Balance, end of year	\$ 258,116	\$ 596,602

Share purchase warrants are considered a derivative liability, as the currency denomination of the exercise price is different from the functional currency of the Company.

The share purchase warrant liability was revalued as at December 31, 2017 and 2016 using the Black-Scholes pricing model with the following assumptions: a risk free interest rate of 1.66% (2016 - 0.63%); an expected volatility of 58-68% (2016 - 76%); an expected life of 1-3 years (2.73 years); a forfeiture rate of zero; and an expected dividend of zero.

### 10. EQUITY

#### 10.1 Authorized share capital

The Company has authorized the issuance of an unlimited number of common and preferred shares with no par value. As at December 31, 2017, the Company had 83,619,850 (2016 - 74,766,046) common shares outstanding and no preferred shares outstanding.

#### 10.2 Issued share capital

During the year ended December 31, 2017, the Company completed the following equity transactions:

- In July 2017, the Company closed a non-brokered private placement for gross proceeds of C\$1,141,904 (\$916,995) through the issuance of 4,391,938 units at a price of C\$0.26 per unit. Each unit consists of one common share and one-half of one share purchase warrant. Each whole warrant entitles the holder thereof to purchase one common share at a price of C\$0.36 per share for a period of three years. The warrants were valued on a relative fair value basis at \$165,249. The Company paid cash finders' fees and other fees of \$37,432.

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### 10. EQUITY (Continued)

---

#### 10.2 Issued share capital (Continued)

The Company issued 138,000 finder's warrants on the same terms as the warrants in this private placement. The finder's warrants were valued at \$13,446. The warrants and the finder's warrants were valued using the Black-Scholes pricing model with the following assumptions: a risk free interest rate of 0.79%; an expected volatility of 72.6%; an expected life of 3 years; a forfeiture rate of zero; and an expected dividend of zero.

The Company issued 1,695,968 share purchase warrants (excluding the finder's warrants) as part of the private placement and 500,000 share purchase warrants are to be issued to an insider of the Company subject to disinterested shareholder and TSX approval.

- In October 2017, the Company issued 750,000 common shares to settle \$123,466 of outstanding employee remuneration. As a result, \$123,466 was reclassified from contributed surplus to share capital. The Company paid cash share issue fees of \$5,167.
- In October 2017, the Company issued 87,500 common shares valued at \$15,728 for consulting services.
- In December 2017, the Company closed the first tranche of a non-brokered private placement for gross proceeds of C\$558,750 (\$436,942) through the issuance of 2,235,000 units at a price of C\$0.25 per unit. Each unit consists of one common share and one-half of one share purchase warrant. Each whole warrant entitles the holder thereof to purchase one common share at a price of C\$0.35 per share for a period of three years. The warrants were valued on a relative fair value basis at \$28,462. The Company paid cash finders' fees and other fees of \$12,407.

The Company issued 60,000 finder's warrants on the same terms as the warrants in this private placement. The finder's warrants were valued at \$2,766. The warrants and the finder's warrants were valued using the Black-Scholes pricing model with the following assumptions: a risk free interest rate of 1.64%; an expected volatility of 62.4%; an expected life of 3 years; a forfeiture rate of zero; and an expected dividend of zero.

The Company issued 617,500 share purchase warrants (excluding the finder's warrants) as part of the private placement and 500,000 share purchase warrants are to be issued to an insider of the Company subject to disinterested shareholder and TSX approval.

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### 10. EQUITY (Continued)

---

#### 10.2 Issued share capital (Continued)

- During the year ended December 31, 2017, the Company issued 1,100,918 common shares to settle \$234,652 owing pursuant to the Company's employee share purchase plan ("ESPP") and 288,448 common shares to settle \$61,060 owing pursuant to the Company's director services agreements ("DSA").

During the year ended December 31, 2016, the Company completed the following equity transactions:

- In August 2016, the Company issued 1,140,626 common shares to settle interest payable of \$532,800 pertaining to the Shareholders Loan Agreement (Note 7.1). The fair value differential between the common shares issued and the carrying value of the interest settled resulted in an increase of \$282,126 to contributed surplus due to the shareholders' existing ownership interest in the Company.
- In August 2016, the Company issued 812,500 common shares to settle \$169,933 of outstanding employee remuneration. As a result, \$169,933 was reclassified from contributed surplus to share capital.
- In September 2016, the Company closed a non-brokered private placement for gross proceeds of C\$2,218,401 (\$1,701,930) through the issuance of 9,243,336 units at a price of C\$0.24 per unit. Each unit consists of one common share and one-half of one share purchase warrant. Each whole warrant entitles the holder thereof to purchase one common share at a price of C\$0.35 per share for a period of three years from closing. The warrants were valued on a relative fair value basis at \$346,969. The Company paid cash finder's fees and other fees of \$51,408.

The warrants were valued using the Black-Scholes pricing model with the following assumptions: a risk free interest rate of 0.64%; an expected volatility of 80%; an expected life of 3.0 years; a forfeiture rate of zero; and an expected dividend of zero.

- During the year ended December 31, 2016, the Company issued 1,130,664 common shares valued at \$280,401 to settle trade and other payables of \$355,658. As a result, the Company recorded a gain on settlement of trade and other payables of \$75,257.
- During the year ended December 31, 2016, the Company issued 1,465,950 common shares to settle \$343,718 owing pursuant to the Company's ESPP and 640,656 common shares to settle \$158,464 owing pursuant to the Company's DSA. As a result, \$502,182 was reclassified from contributed surplus to share capital.

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

(Expressed in U.S. Dollars, unless otherwise indicated)

### 10. EQUITY (Continued)

#### 10.3 Share purchase warrants

The continuity of share purchase warrants for the year ended December 31, 2017 is as follows:

Expiry date	Exercise price	Balance, December 31, 2016	Issued	Exercised	Expired	Balance, December 31, 2017
September 23, 2019	\$ 0.35	4,621,655	-	-	-	4,621,655
July 27, 2020	\$ 0.36	-	1,833,968	-	-	1,833,968
December 22, 2020	\$ 0.35	-	677,500	-	-	677,500
		4,621,655	2,511,468	-	-	7,133,123
Weighted average exercise price	\$	0.35	\$ 0.36	\$ -	\$ -	\$ 0.35

The weighted average remaining contractual life is 2.06 years.

The continuity of share purchase warrants for the year ended December 31, 2016 is as follows:

Expiry date	Exercise price	Balance, December 31, 2015	Issued	Exercised	Expired	Balance, December 31, 2016
February 26, 2016	\$ 2.00	1,500,000	-	-	(1,500,000)	-
February 26, 2016	\$ 1.15	84,980	-	-	(84,980)	-
October 24, 2016	\$ 1.00	4,169,067	-	-	(4,169,067)	-
September 23, 2019	\$ 0.35	-	4,621,655	-	-	4,621,655
		5,754,047	4,621,655	-	(5,754,047)	4,621,655
Weighted average exercise price	\$	1.26	\$ 0.35	\$ -	\$ 1.26	\$ 0.35

#### 10.4 Equity instrument issued to Powerlite Ventures Limited

The Company is party to a credit facility with Powerlite Ventures Limited ("Powerlite") for \$21,000,000 of which the Company drew down and, in 2014, repaid \$18,000,000 through the issuance of shares leaving an available balance of \$3,000,000. The Company believes it is unlikely that Powerlite will be able to fund the remaining amount of the facility.

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **10. EQUITY (Continued)**

---

#### **10.5 Equity settled compensation arrangements**

##### **ESPP**

In 2015, the Company adopted an ESPP. The Company is authorized to issue up to 3,000,000 common shares pursuant to the terms and conditions of the ESPP. Employees, who elect to participate in the ESPP, can contribute up to 50% of their salary (the "Employee Contribution"). The Company will then match 66.67% of the Employee's Contribution (the "Matching Contribution"). The purchase price of the common shares is calculated based on the five-day volume weighted average trading price of the common shares immediately preceding the end of each calendar quarter. The Employee Contribution and the Matching Contribution are expensed in the period in which they are incurred with the offsetting amount being recorded in contributed surplus until the common shares are issued.

During the year ended December 31, 2017, Employee Contributions totaled \$143,366 (2016 - \$126,476) and Matching Contributions totaled \$95,574 (2016 - \$84,313). As at December 31, 2017 and to date, a total of 2,566,868 and 2,917,805 common shares had been issued, respectively, pursuant to the ESPP.

##### **DSA**

In 2015, the Company adopted the DSA. The Company is authorized to issue up to 2,000,000 common shares pursuant to the terms and conditions of the DSA. Directors who elect to participate in the DSA contribute 50% of their director fee/salary to the ESPP and the remaining 50% of their director fee/salary is settled through the issuance of common shares in accordance with the DSA. The purchase price of the common shares is calculated based on the five-day volume weighted average trading price of the common shares immediately preceding the end of each calendar quarter. Amounts settled in accordance with the DSA are expensed in the period in which they are incurred with the offsetting amount being recorded in contributed surplus until the common shares are issued.

During the year ended December 31, 2017, \$61,766 (2016 - \$66,060) was expensed under the DSA. As at December 31, 2017 and to date, a total of 929,104 and 1,022,115 common shares had been issued, respectively, pursuant to DSA.

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

### 11. SHARE OPTION RESERVE

#### 11.1 Stock option plan

On October 28, 2014, the Company adopted a new stock option plan, which permits the Board of Directors of the Company to grant stock options to acquire common shares of the Company to eligible persons. The Company is authorized to issue stock options for a maximum of 7,271,816 common shares pursuant to the stock option plan. The stock option plan permits the Board of Directors of the Company to set the terms for each stock option grant; however, stock options granted under the plan cannot exceed a maximum exercise period of 5 years. The options are non-transferable.

#### 11.2 Stock option continuity

The continuity of stock options for the year ended December 31, 2017 is as follows:

<u>Expiry date</u>	<u>Exercise price</u>	<u>Balance, December 31, 2016</u>	<u>Issued</u>	<u>Exercised</u>	<u>Expired/ Forfeited</u>	<u>Balance, December 31, 2017</u>				
May 14, 2017	\$ 2.00	225,000	-	-	(225,000)	-				
April 30, 2018	\$ 1.20	165,163	-	-	-	165,163				
August 6, 2018	\$ 0.35	1,000,000	-	-	-	1,000,000				
November 3, 2018	\$ 1.20	15,513	-	-	-	15,513				
November 3, 2018	\$ 1.50	54,750	-	-	-	54,750				
October 27, 2019	\$ 1.20	393,336	-	-	-	393,336				
May 19, 2020	\$ 0.335	1,040,000	-	-	(10,000)	1,030,000				
May 19, 2021	\$ 0.36	1,185,000	-	-	-	1,185,000				
May 16, 2022	\$ 0.32	-	2,060,000	-	-	2,060,000				
		4,078,762	2,060,000	-	(235,000)	5,903,762				
Weighted average exercise price	\$	0.58	\$	0.32	\$	-	\$	1.93	\$	0.43

As at December 31, 2017, 4,135,429 stock options were exercisable.

The weighted average remaining contractual life is 2.86 years.

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

### 11. SHARE OPTION RESERVE (Continued)

#### 11.2 Stock option continuity (Continued)

The continuity of stock options for the year ended December 31, 2016 is as follows:

Expiry date	Exercise price	Balance, December 31, 2015	Issued	Exercised	Expired/ Forfeited	Balance, December 31, 2016				
May 14, 2017	\$ 2.00	235,000	-	-	(10,000)	225,000				
April 30, 2018	\$ 1.20	260,976	-	-	(95,813)	165,163				
August 6, 2018	\$ 0.35	1,000,000	-	-	-	1,000,000				
November 3, 2018	\$ 1.20	15,513	-	-	-	15,513				
November 3, 2018	\$ 1.50	54,750	-	-	-	54,750				
October 27, 2019	\$ 1.20	2,650,754	-	-	(2,257,418)	393,336				
May 19, 2020	\$ 0.335	1,285,000	-	-	(245,000)	1,040,000				
June 2, 2020	\$ 0.375	20,000	-	-	(20,000)	-				
May 19, 2021	\$ 0.36	-	1,235,000	-	(50,000)	1,185,000				
		5,521,993	1,235,000	-	(2,678,231)	4,078,762				
Weighted average exercise price	\$	0.88	\$	0.36	\$	-	\$	1.10	\$	0.58

#### 11.3 Share-based compensation

During the year ended December 31, 2017, the Company recognized share-based compensation expense of \$230,698 (2016 - \$175,766), of which \$198,706 (2016 - \$147,909) has been allocated to administrative expenses and \$31,992 (2016 - \$27,857) has been allocated to exploration and evaluation assets.

In May 2017, the Company granted 2,060,000 stock options to officers, employees, directors and other eligible persons at an exercise price of C\$0.32 with an expiry date of May 16, 2022. The weighted average fair value of the options granted was estimated at C\$0.17 per option at the grant date using the Black-Scholes Option Pricing model with the following assumptions: a risk free interest rate of 1.12%; an expected volatility of 79%; an expected life of 5 years; a forfeiture rate of zero; and an expected dividend of zero.

In May 2016, the Company granted 1,235,000 stock options to officers, employees, directors and other eligible persons at an exercise price of C\$0.36 with an expiry date of May 19, 2021. The weighted average fair value of the options granted was estimated at C\$0.21 per option at the grant date using the Black-Scholes Option Pricing model with the following assumptions: a risk free interest rate of 0.69%; an expected volatility of 79%; an expected life of 5 years; a forfeiture rate of zero; and an expected dividend of zero.

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

(Expressed in U.S. Dollars, unless otherwise indicated)

### 12. ADMINISTRATIVE EXPENSES

	Year ended December 31,	
	2017	2016
Salaries and benefits	\$ 984,264	\$ 1,077,241
Consulting and professional fees	233,328	150,386
Corporate administration	240,807	172,662
Depreciation	2,123	6,015
Share-based compensation	198,706	147,909
	\$ 1,659,228	\$ 1,554,213

### 13. FINANCE COSTS

	Note	Year ended December 31,	
		2017	2016
Interest expense on shareholder loan	7.1	\$ 209,670	\$ 178,489
Interest expense on other loans payable	7.2	6,808	10,012
Other interest expense		-	2,579
		\$ 216,478	\$ 191,080

### 14. UNREALIZED GAIN (LOSS)

	Note	Year ended December 31,	
		2017	2016
Gain (loss) on revaluation of investment in URI	5.1	\$ 25,412	\$ (645,230)
Loss on revaluation of investment in Western Uranium	5.2	-	(298,311)
Gain (loss) on warrant liabilities	9	570,389	(260,619)
		\$ 595,801	\$ (1,204,160)



# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

### 15. REALIZED GAIN (LOSS)

	Note	Year ended December 31,	
		2017	2016
Loss on sale of investment in URI	5.1	\$ (22,570)	\$ (72,050)
Loss on sale of investment in Western Uranium	5.2	-	(148,141)
Gain on sale of exploration and evaluation assets held for sale	6.3	-	154,092
Gain on settlement of trade and other payables	10.2	-	75,257
Other gains		18,632	11,127
		\$ (3,938)	\$ 20,285

### 16. RELATED PARTY TRANSACTIONS AND BALANCES

#### 16.1 Related party transactions

During the years ended December 31, 2017 and 2016, the Company had related party transactions with the Company's directors, management and shareholders including:

- Interest accruing to certain directors/shareholders of the Company on the Shareholders Loan Agreement (Note 7.1);
- The extension of the term of the Shareholders Loan Agreement and other amendments and agreements related to the Shareholders Loan Agreement as disclosed (Note 7.1); and
- The issuance of common shares to key management personnel of the Company to settle trade and other payables, employee remuneration (Note 10.2) and interest on the Shareholders Loan Agreement (Note 7.1).

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

### 16. RELATED PARTY TRANSACTIONS AND BALANCES (Continued)

#### 16.2 Key management personnel compensation

The remuneration of the Company's directors and other key management personnel, being those who have the authority and responsibility for planning, directing and controlling the activities of the Company, consist of the following amounts:

	Year ended December 31,	
	2017	2016
Salaries and benefits	\$ 731,926	\$ 871,312
Share-based compensation	176,296	87,194
	\$ 908,222	\$ 958,506

#### 16.3 Related party liabilities

	As at December 31,	
	2017	2016
Loan payable to shareholders	\$ 2,057,805	\$ 1,848,135
Trade and other payables for key management personnel - current	716,838	339,043
Trade and other payables for key management personnel - non-current	-	310,000
	\$ 2,774,643	\$ 2,497,178

Included in trade and other payables as at December 31, 2017 is \$512,500 (2016 - \$557,500) owing to a director of the Company of which \$325,000 (2016 - \$370,000) is related to a severance agreement and \$187,500 (2016 - \$187,500) is related to a deferred compensation agreement. During the year ended December 31, 2017, the Company paid this director \$45,000 (2016 - \$60,000) towards the severance agreement. On February 14, 2018, the Company entered into an amended severance agreement with this director to defer the remaining severance payments over 48 months, whereby the amount payable was increased to \$370,000. The Company and this director have agreed to settle the deferred compensation of \$187,500 by the issue of up to 578,822 common shares of the Company before June 30, 2018.

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

(Expressed in U.S. Dollars, unless otherwise indicated)

### 17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

#### 17.1 Categories of financial instruments

Financial instruments are classified into one of the following categories: FVTPL; loans and receivables; or other financial liabilities. The carrying values of the Company's financial instruments are classified into the following categories:

Financial assets	Note	As at December 31,	
		2017	2016
<b>Loans and receivables</b>			
Cash		\$ 432,192	\$ 941,370
Restricted cash		39,176	42,687
<b>Fair value through profit or loss</b>			
Investment in URI	5.1	-	68,264
		\$ 471,368	\$ 1,052,321

Financial liabilities	Note	As at December 31,	
		2017	2016
<b>Other financial liabilities</b>			
Trade and other payables		\$ 1,525,906	\$ 1,376,872
Loan payable to shareholders	7	2,057,805	1,848,135
Other loans payable	7	46,873	90,065
Decommissioning liability	8	142,918	129,933
<b>Fair value through profit or loss</b>			
Warrant liabilities	9	258,116	596,602
		\$ 4,031,618	\$ 4,041,607

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### 17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Continued)

---

#### 17.2 Fair value

The fair value of financial assets and financial liabilities measured at amortized cost is determined in accordance with generally accepted pricing models based on discounted cash flow analysis or using prices from observable current market transactions. The Company considers that the carrying amount of all its financial assets and financial liabilities measured at amortized cost approximates their fair value.

The fair values of the Company's financial instruments classified as FVTPL are determined as follows:

- The fair value of financial instruments that are traded on an active liquid market are determined with reference to the quoted market prices. The fair value of the Company's investments were determined using this methodology.
- The fair value of financial instruments that are not traded in an active market are determined using generally accepted valuation models using inputs that are directly (i.e. prices) or indirectly (i.e. derived prices) observable. The fair value of the warrant liability is determined using the Black-Scholes Option Pricing model.
- The fair value of financial instruments that are not traded in an active market are determined using generally accepted valuation models using inputs that are not directly (i.e. prices) or indirectly (i.e. derived from prices) observable.

The fair value of all other financial instruments of the Company approximates their carrying value because of the demand nature or short-term maturity of these instruments. The Company's cash, restricted cash and other financial liabilities are carried at amortized cost.

The Company's financial instruments recorded at fair value require disclosure about how the fair value was determined based on significant levels of inputs described in the following hierarchy:

- Level 1 fair value measurements are those derived from quoted prices in active markets for identical assets or liabilities.
- Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1, that are observable either directly or indirectly.
- Level 3 fair value measurements are those derived from valuation techniques that include inputs that are not based on observable market data.

The fair value of the Company's investment in URI was recorded at fair value using Level 1 of the fair value hierarchy. The fair value of the Company's warrant liabilities is recorded at fair value using Level 2 of the fair value hierarchy.

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### 17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Continued)

---

#### 17.3 Financial risk management objectives and policies

The financial risk arising from the Company's operations are market risk, credit risk, and liquidity risk. These risks arise from the normal course of operations and all transactions undertaken are to support the Company's ability to continue as a going concern. The risks associated with these financial instruments and the policies on how to mitigate these risks are set out below. Management of the Company manages and monitors these exposures to ensure appropriate measures are implemented on a timely and effective manner. During the year ended December 31, 2017, there were no significant changes in the Company's financial risk management objectives and policies. The Company's risk exposure and the impact on the Company's financial instruments are summarized below:

##### Market risk

Market risk is the risk that the fair value of the future cash flows of a financial instrument will fluctuate due to changes in market factors. Market risk comprises three types of risks: currency risk, price risk and interest rate risk:

##### Currency risk

Currency risk is the risk that the fair values or future cash flows of the Company's financial instruments will fluctuate because of changes in foreign currency exchange rates. The Company is exposed to currency risk through financial assets and liabilities denominated in currencies other than the United States Dollar. Management believes the currency risk related to currency conversions is minimal and therefore, does not hedge its currency risk.

##### Price risk

Price risk is the risk that the fair value of future cash flows of the Company's financial instruments will fluctuate because of changes in market prices. The Company is exposed to the risk of fluctuations in prevailing market prices for its uranium products. However, as the Company is currently an exploration and development stage company, the risk is insignificant.

##### Interest rate risk

Interest rate risk is the risk that the fair values and future cash flows of the Company will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk to the extent that the cash maintained at the financial institutions is subject to a floating rate of interest. The interest rate risk on cash is not significant.

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Continued)**

---

#### **17.3 Financial risk management objectives and policies (Continued)**

##### **Interest rate risk (Continued)**

The Company's Shareholders Loan Agreement (Note 7.1) accrues interest at a fixed rate; therefore, the Company is not exposed to interest rate risk on this instrument. The Company's other loans payable (Note 7.2) are non-interest bearing and interest is calculated using an effective interest rate.

##### **Credit risk**

Credit risk is the risk of potential loss to the Company if the counterparty to a financial instrument fails to meet its contractual obligations.

The Company is exposed to credit risk associated with its cash. The Company's maximum exposure to credit risk is equal to the carrying amount of its cash.

The Company's credit risk on cash arises from default of the counterparty. The Company limits its exposure to counterparty credit risk on cash by only dealing with financial institutions with high credit ratings.

##### **Liquidity risk**

Liquidity risk is the risk that the Company will not be able to settle or manage its obligations associated with financial liabilities. The Company's approach to managing liquidity is to evaluate current and expected liquidity requirements under both normal and stressed conditions to ensure that it maintains sufficient reserves of cash, access to financing facilities or access to cash generating opportunities, such as the liquidation of non-core and redundant assets to meet its liquidity requirements in the short and long term. In order to ensure that the Company has sufficient cash, access to financing facilities or access to cash generating opportunities, such as the liquidation of non-core and redundant assets to meet expected expenditures, the Company prepares annual expenditure budgets that are updated as necessary depending on various factors, including capital deployment, progress on permitting, results from the exploration and development of its properties and general industry conditions. The annual and updated budgets are approved by the Board of Directors.

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

### 17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Continued)

#### 17.3 Financial risk management objectives and policies (Continued)

##### Liquidity risk (Continued)

The Company's current and expected remaining contractual maturities for its financial liabilities with agreed repayment periods are presented below. The table includes the undiscounted cash flows of financial liabilities based on the earliest date on which the Company can be required to satisfy the liabilities.

As at December 31, 2017	3 months -			Total
	1-3 months	1 year	1-5 years	
Trade and other payables	\$ 1,525,906	\$ -	\$ -	\$ 1,525,906
Loan payable to	-	281,805	1,776,000	2,057,805
Other loans payable	-	46,873	-	46,873
	\$ 1,525,906	\$ 328,678	\$ 1,776,000	\$ 3,630,584

### 18. CAPITAL RISK MANAGEMENT

The Company's capital risk management objectives are to safeguard the Company's ability to continue as a going concern in order to support the Company's exploration and development of its mineral properties and to maintain a flexible capital structure which optimizes the costs of capital at an acceptable risk.

The Company depends on external financing to fund its activities and there can be no guarantee that external financing will be available at terms acceptable to the Company. The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may issue new shares, issue new debt or acquire or dispose of assets. In order to facilitate the management of its capital requirements, the Company prepares annual expenditure budgets that are updated as necessary depending on various factors, including capital deployment, progress on permitting, results from the exploration and development of its properties and general industry conditions. The annual and updated budgets are approved by the Board of Directors. During the year ended December 31, 2017, there were no significant changes in the processes used by the Company or in the Company's objectives and policies for managing its capital. The Company is not subject to any externally imposed capital requirements.

As at December 31, 2017, the Company's capital structure consists of loans payable (Note 7) and the equity of the Company (Note 10).

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

### 19. COMMITMENTS

As at December 31, 2017, the Company's commitments that have not been disclosed elsewhere in the consolidated financial statements were as follows:

	Within 1 year	2-4 years	Over 4 years	Total
Operating lease	\$ 45,847	\$ 7,667	\$ -	\$ 53,514
Exploration and evaluation	507,738	4,120,283	3,441,651	8,069,672
	\$ 553,585	\$ 4,127,950	\$ 3,441,651	\$ 8,123,186

As at December 31, 2017, exploration and evaluation commitments include lease, mineral claim, exploration license and property purchase agreement payments. Certain of the Company's exploration and evaluation commitments may provide the Company with the ability to avoid funding those commitments; however, the Company discloses the contractual maturities of the Company's exploration and evaluation commitments based on management's intent.

### 20. SUPPLEMENTAL CASH FLOW INFORMATION

During the year ended December 31, 2017, the Company completed the following non-cash investing and financing activities:

- Issued 1,100,918 common shares to settle \$234,652 owing pursuant to the Company's ESPP;
- Issued 288,448 common shares to settle \$61,060 owing pursuant to the Company's DSA;
- Issued 750,000 common shares to settle \$123,466 of outstanding employee remuneration;
- Issued 87,500 common shares to settle \$15,728 of consulting services;
- Allocated share-based compensation of \$31,992 to exploration and evaluation assets;
- Recorded \$394,205 to contributed surplus for equity settled transactions pursuant to the Company's ESPP, DSA, and employee share-based remuneration not issued pursuant to the ESPP and DSA; and
- Issued 2,511,468 share purchase warrants valued at \$209,923 as part of the July and December 2017 financings.



# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

### 20. SUPPLEMENTAL CASH FLOW INFORMATION (Continued)

During the year ended December 31, 2016, the Company completed the following non-cash investing and financing activities:

- Issued 1,130,664 common shares to settle trade and other payables of \$355,658;
- Issued 1,465,950 common shares to settle \$343,718 owing pursuant to the Company's ESPP;
- Issued 640,656 common shares to settle \$158,464 owing pursuant to the Company's DSA;
- Issued 1,140,626 common shares to settle \$532,800 of outstanding interest pertaining to the Shareholders Loan Agreement;
- Issued 812,500 common shares to settle \$169,933 of outstanding employee remuneration;
- Allocated share-based compensation of \$27,857 to exploration and evaluation assets;
- Recorded \$416,984 to contributed surplus for equity settled transactions pursuant to the Company's ESPP, DSA, and employee share-based remuneration not issued pursuant to the ESPP and DSA; and
- Issued 4,621,665 share purchase warrants as part of the September 2016 financing;

No cash interest or income taxes were paid during the years ended December 31, 2017 and 2016.

### 21. NON-CONTROLLING INTEREST

The Company's non-controlling interest relates to its 70% interest in UrAsia.

Changes in the Company's non-controlling interest for the years ended December 31, 2017 and 2016 were as follows:

	Year ended December 31,	
	2017	2016
Balance, beginning of year	\$ 1,246,780	\$ 1,168,628
Plus (less): non-controlling interest from net income (loss)	(1,701,951)	5,271
Plus: non-controlling interest from other comprehensive income	5,175	72,881
Balance, end of year	\$ (449,996)	\$ 1,246,780

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

(Expressed in U.S. Dollars, unless otherwise indicated)

### 21. NON-CONTROLLING INTEREST (Continued)

Set out below is the summarized financial information for 100% of UrAsia's net assets, total comprehensive income (loss) and cash. The information is presented before considering inter-company consolidation and elimination adjustments.

	As at December 31,	
	2017	2016
<b>Current</b>		
Assets	\$ 103,431	\$ 208
Liabilities	(15,451)	(12,934)
Total current net assets (liabilities)	87,980	(12,726)
<b>Non-current</b>		
Assets	4,030,524	10,336,254
Liabilities	(1,020,705)	(2,354,202)
Total non-current net assets	3,009,819	7,982,052
Net assets	\$ 3,097,799	\$ 7,969,326

  

	As at December 31,	
	2017	2016
Net loss before tax	\$ (6,416,438)	\$ (53,801)
Deferred income tax recovery	992,989	7,666
Net loss	(5,423,449)	(46,135)
Other comprehensive income	14,022	252,678
Total comprehensive income (loss)	\$ (5,409,427)	\$ 206,543

  

	Year ended December 31,	
	2017	2016
Net cash used in operating activities	\$ (20,440)	\$ (105,147)
Net cash used in investing activities	(1,051,759)	(93,091)
Net cash generated from financing activities	1,103,534	199,514
Net increase in cash	31,335	1,276
Cash, beginning of year	585	1,181
Effect of foreign exchange rate changes on cash	(1,364)	(1,872)
Cash, end of year	\$ 30,556	\$ 585

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

(Expressed in U.S. Dollars, unless otherwise indicated)

### 22. DEFERRED INCOME TAX

#### 22.1 Deferred income tax

Taxation on profits or losses has been calculated on the estimated assessable profits or losses for the year at the rates of taxation prevailing in the jurisdictions in which the Company operates.

#### 22.2 Deferred income tax expenses

	Year ended December 31,	
	2017	2016
Net loss before income tax	\$ 7,516,632	\$ 2,846,945
Statutory tax rate	26%	26%
Deferred income tax recovery based on statutory rate	\$ 1,954,000	\$ 740,000
Effect of different tax rates applicable in foreign jurisdictions	(982,000)	(275,000)
Effect of reduction in foreign statutory rate	1,286,000	-
Unrecognized deferred tax assets	(283,000)	(162,000)
Effect of non-deductible expenses and non-taxable revenue and other	261,000	(569,000)
Deferred income tax recovery (expense)	\$ 2,236,000	\$ (266,000)

In December 2017, the US government enacted the Tax Cuts and Jobs Act of 2017 ("the Act") which reduced the statutory tax rate from 34% to 21%. The impact of this legislation created a \$1.3 million tax recovery due to the re-measurement of the Company's deferred tax liabilities at the new US federal tax rate of 21%.

#### 22.3 Deferred tax balances

The Company's deferred tax liabilities consist of the following amounts:

	As at December 31,	
	2017	2016
Exploration and evaluation assets	\$ 2,920,790	\$ 5,121,370
Inter-company loans eliminated on consolidation	1,132,000	1,167,420
Deferred tax liabilities	\$ 4,052,790	\$ 6,288,790

As at December 31, 2017 and 2016, the Company has not recognized any deferred tax assets.

# AZARGA URANIUM CORP.

## Notes to the Consolidated Financial Statements

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

### 22. DEFERRED INCOME TAX (Continued)

#### 22.3 Deferred tax balances (Continued)

Changes in the Company's deferred tax liabilities for the years ended December 31, 2017 and 2016 were as follows:

	Year ended December 31,	
	2017	2016
Opening balance	\$ 6,288,790	\$ 6,022,790
Deferred income tax (recovery) expense	(2,236,000)	266,000
Deferred tax liabilities	\$ 4,052,790	\$ 6,288,790

#### 22.4 Unrecognized deductible temporary differences and unused tax losses

The Company's deductible temporary differences and unused tax losses for which no deferred tax asset is recognized consist of the following tax affected amounts:

	As at December 31,	
	2017	2016
Non-capital losses	\$ 2,509,000	\$ 2,175,000
Deductible temporary differences	110,000	161,000
Total unrecognized amounts	\$ 2,619,000	\$ 2,336,000

As at December 31, 2017, the Company had unrecognized deferred tax assets attributable to deductible temporary differences of \$110,000 (2016 - \$161,000) which are primarily related to value added tax receivables and certain deferred payments not being recognized.

The deferred tax assets related to the temporary differences and non-capital losses were not recognized as their recoverability was not considered to be probable.

#### 22.5 Expiry dates

The expiry dates of the Company's unused tax losses are as follows:

	As at December 31, 2017	
<b>Non-capital losses</b>		
Kyrgyz Republic	\$ 3,510,000	2018 - 2022
Hong Kong	631,000	Indefinite
Canada	4,180,000	2032 - 2037
United States	4,412,000	2034 - 2037
	\$ 12,733,000	

# **AZARGA URANIUM CORP.**

## **Notes to the Consolidated Financial Statements**

For the year ended December 31, 2017

*(Expressed in U.S. Dollars, unless otherwise indicated)*

---

### **23. SUBSEQUENT EVENTS**

---

Subsequent to December 31, 2017, the Company completed the following transactions:

- In January 2018, the Company issued 350,937 common shares to settle \$60,901 owing pursuant to the Company's ESPP and 93,011 common shares to settle \$16,141 owing pursuant to the Company's DSA.
- In January 2018, the Company closed the second and final tranche of its non-brokered private placement of C\$195,000 through the issuance of 780,000 units at a price of C\$0.25 per unit. Each unit consists of one common share of the Company and one-half of one share purchase warrant. Each whole warrant entitles the holder thereof to purchase one common share at a price of C\$0.35 per share for a period of three years.
- In February 2018, the Company entered into an amended severance agreement to defer the remaining severance payments over 48 months as discussed in note 16.3.
- In March 2018, the Company received conditional TSX approval to issue up to 186,512 common shares in settlement of C\$46,628 of trade and other payables.
- In March 2018, the Company received conditional TSX approval to issue up to 162,900 common shares in settlement of \$32,103 of trade and other payables.
- In March 2018, the Company received conditional TSX approval to issue up to 125,000 common shares to buy back a royalty on the Dewey Burdock Project.